Medical Digest & Congress Report

Professor Mikhail Kosiborod going to speaking about the additional analysis from the EMPULSE trial that were presented at the American College of Cardiology congress. The trial demonstrated the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure. Video: https://congressreport.eu/scientific-contents/interview:results-empuls...

Professor Deepak Bhatt had presented an analysis from the SCORED trial at the American College of Cardiology Annual Sessions as a late-breaking clinical trial. Video: https://congressreport.eu/scientific-contents/interview:effect-sotagliflozin-cardiovascular-and-renal-events-patients-type-2-diabetes-and-moderate-renal-impairment-who-are-cardiovascular-risk-scored-trial

Professor Federico Cappuzzo gave us an update on the emerging data on the field of lung cancer. There are very important news that were presented during the ESMO, ELCC and EACR. These data are clearly changing the standard of care of patients with early stage Non-Small-Cell Lung Cancer. In this field we have data from two very important trial: the IMpower010 and the KEYNOTE-09. Video: https://cong...

Professor Deepak Bhatt gave us a brief recap of some data he presented at the ACC Late-Braker session. He presented data about a drug know as Bentracimab,which it is an investigational agent, a human monoclal antibody that it is been desigend to reverse the effect of the anti-platelet drug Ticagrelor. Video: https://congressreport.eu/scientific-contents/interview:bentracimab-immediately-and-signif...

Professor John Camm recently attended the European Heart Rhythm Association annual congress.  One of the session he involved in wanted to group together the challenging cases in the topic. Video: https://congressreport.eu/scientific-contents/interview:protecting-comorbid-patients-atrial-fibrillation-stroke

Professor Manesh Patel speak about how to reduce limb events, amputations and making our patients limbs to better with peripheral arterial disease. Video: https://congressreport.eu/scientific-contents/interview:how-reduce-limb-events-including-amputations-our-patients

Professor David Lanfear summarize the key interesting things from the American College of Cardiology 2022 Scientific sessions in the topic. Video: https://congressreport.eu/scientific-contents/interview:guidance-heart-failure-care-acc-2022

Professor Cecilia Linde gave us an update from the European Heart Rhythm Association conference from Copenhagen on four topics regarding the EHRA scientific documents. 1. Interaction between electrical implantable devices and medical procedures 2. Mitral valve prolapse 3. Novel oral anticoagulants, NOACs 4. Leadless Pacemaker Video: https://congressreport.eu/scientific-contents/interview:ehra-scie...

Professor Florian Rader presented this year at ACC 2022 the results of the MAVA-LTE Study. As the backdrop of this study, Hypertrophic Cardiomyopathy is a disease known for now over 70 years, and in these years we haven't had any specific medication  that targets the underline mechanism of this disorder. Video: https://congressreport.eu/scientific-contents/interview:updated-cumulative-results...

Prof. David F. McDermott shared his thoughts in the kidney cancer filed. What was the biggest changes in the last six months? Video: https://congressreport.eu/scientific-contents/standalonecontent:role-immune-checkpoint-inhibitors-and-vegf-tkis-adjuvant-treatment-renal-cell-carcinoma

Prof. Camillo Porta shared his thoughts on the ASCO GU 2022 meeting which focused on the renal cell carcinoma updates. Which were those changes what we can apply in our daily practice? Video: https://congressreport.eu/scientific-contents/standalonecontent:how-will-current-therapeutic-options-change-treatment-rcc-daily-practice

Professor Stefan N. Symeonides gave us a talk about the results from 30-month follow-up of KEYNOTE-564. Video: https://congressreport.eu/scientific-contents/standalonecontent:pembrolizumab-post-nephrectomy-adjuvant-therapy-patients-renal-cell-carcinoma

Professor Oliver Sartor gave us a talk about the newer concepts around the treatment intensification in prostate cancer, focus a little bit on the newer darolutamide and a PARP inhibitor studies. Video: https://congressreport.eu/scientific-contents/standalonecontent:treatment-intensification-treatment-prostate-cancer

Professor Ken Kato gave us a talk about longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. Video: https://congressreport.eu/scientific-contents/standalonecontent:first-line-pembrolizumab-plus-chemotherapy-versus-chemotherapy-advanced-esophageal-cancer

Professor Matthew R. Zibelman gave us updates in bladder or urothelial cancers after the recent ASCO GU symposium 2022 from San Francisco. Video: https://congressreport.eu/scientific-contents/standalonecontent:state-art-treatment-bladder-cancer

Professor Piotr Ponikowski gave us a talk about iron deficiency in heart failure in the context of prevalence, clinical significance and potential therapeutic consequences. Video: https://congressreport.eu/scientific-contents/standalonecontent:treatment-iron-deficiency-acute-and-chronic-heart-failure

Professor Hubert Seggewiss gave us a talk about alcohol septal ablation in hypertrophic cardiomyopathy. Video: https://congressreport.eu/scientific-contents/standalonecontent:alcohol-septal-ablation-hypertrophic-cardiomyopathy-past-and-future

Professor Petar Seferovic gave us a talk on the new drugs and strategies regarding the heart failure. He spoke about SGLT2 inhibitors too, which are one of the most important breaktroughs in the treatemnt of heart failure. Video: https://congressreport.eu/scientific-contents/standalonecontent:use-sglt2-inhibitors-prevention-and-treatment-heart-failure

Professor Iacopo Olivotto gave us a talk on new developments about myosin inhibitors and that use in hypertrophic cardiomyopathy. Last year they presented EXPLORER-HCM study, since then several things happened. Video: https://congressreport.eu/scientific-contents/standalonecontent:direct-myosin-inhibitors-hypertrophic-cardiomyopathy-new-era

Diagnostic delays in pulmonary arterial hypertension are related to increased morbidity and mortality. The risk of a delayed, or even a missed, diagnosis is high as the conditions are rare. The aim of the study was to describe patients’ and spouses’ experiences of the journey from the first symptom to an established diagnosis. The study: https://journals.sagepub.com/doi/10.1177/21501327211029241 V...

In this review, Dr. Babak Dehestani aim to explain the mechanism of action of Liraglutide, its pharmacokinetic properties, its clinical impact on obesity and its safety and tolerability. Video: https://congressreport.eu/scientific-contents/standalonecontent:clinical-impact-liraglutide-treatment-obesity-2

Professor Michael Camilleri gave us a review on the topic. Video: https://congressreport.eu/scientific-contents/standalonecontent:association-glp-1-analogs-and-agonists-administered-obesity-weight-loss-and-adverse-events

Professor Andrzej Jakubowiak speak about the novelties and state of the art treatment presented at ASH 2021. Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-multiple-myeloma-2021

Interview with professor Lisa K. Hicks: Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH RC COVID-19 Registry for Hematology. Video: https://congressreport.eu/scientific-contents/inter...

Professor Srdan Verstovsek speak about the novelties and state of the art treatment presented at ASH 2021. Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-myelofibrosis-and-polycythemia-vera-2021